The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| COGT | +47.46% | +51.22% | +8.61% | +55% |
| S&P | +12.65% | +91.73% | +13.89% | +114% |
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
No news articles found for Cogent Biosciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$1.15M | -4.6% |
| Market Cap | $2.01B | 69.7% |
| Market Cap / Employee | $9.79M | 0.0% |
| Employees | 205 | 25.0% |
| Net Income | -$80.93M | -14.6% |
| EBITDA | -$82.21M | -10.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $125.30M | 29.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $58.85M | 260.9% |
| Short Term Debt | $1.71M | 12.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -72.69% | -7.2% |
| Return On Invested Capital | -56.03% | -1.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$64.35M | -23.1% |
| Operating Free Cash Flow | -$64.29M | -23.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.22 | 4.54 | 7.38 | 34.72 | 493.89% |
| Price to Tangible Book Value | 4.22 | 4.54 | 7.38 | 34.72 | 493.89% |
| Enterprise Value to EBITDA | -9.68 | -7.57 | -10.11 | -21.32 | 61.25% |
| Return on Equity | -99.5% | -84.0% | -107.6% | -95.4% | 21.58% |
| Total Debt | $17.47M | $17.09M | $60.66M | $60.56M | 239.67% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
